Objective To evaluate safety and mechanism of action of mezagitamab (TAK-079), an anti-CD38 monoclonal antibody, in patients with moderate to severe systemic lupus erythematosus (SLE). Methods A phase ...
1 West China Hospital affiliated Sichuan University, Department of Laboratory Medicine, Chengdu, China 2 West China Hospital affiliated Sichuan University, Department of Rheumatology, Chengdu, China 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback